Improving Absorption and Targeting of Antiviral Drugs

描述（由申请人提供）：随着最近令人不安的事件预示着紧迫感的增加，NIAID已经针对天花（天花）的治疗方法、疫苗、佐剂/免疫刺激剂和诊断进行了研究和开发。TSRL被授予I期SBIR，以探索药物前策略，以增加潜在抗天花药物的口服可用性。能够提高已批准药物和潜在候选药物的口服生物利用度的策略将有助于开发更有效的抗病毒药物，并减少诸如药物毒性、患者依从性差和高成本等不良后果。该生物防御项目的长期目标是通过设计针对人体肠道中表达的转运蛋白的前药，并能够被内源性酯酶或氨基酶激活，从而将吸收的药物从其前药形式释放到体内，从而改善强效但吸收不良的抗痘药物的口服吸收。在这个项目中，我们与南加州大学的Charles McKenna教授（前药设计和合成）和密歇根大学的John Drach教授（病毒学研究）建立了合作关系。I期项目的工作主要集中于环西多福韦（cHPMPC）的前药，这是一种广谱抗病毒化合物，对天花病毒和其他正痘病毒具有有效活性，但由于其口服生物利用度非常低，在天花流行中价值有限。我们证明了在麦肯纳教授实验室首次发现的cHPMPC二肽前药具有很大的口服给药潜力。我们的动物口服生物利用度模型的结果表明，第一代二肽前药的吸收比母体药物cHPMPC高出一个数量级，并且吸收的前药中有很大一部分在体内转化为药物。在这个II期SBIR提案中，我们设计了一个合成策略和SAR计划来优化这类新的前药的生物利用度。我们已经形成了一个由研究人员和专家组成的合作网络，这将使我们能够在公认的动物模型中系统地测试各种新型cHPMPC二肽偶联物库的稳定性、转运性、药物口服生物利用度和有效性。具有最佳口服吸收和功效的化合物或化合物将按照GMP要求生产并进行毒性测试。药代动力学、代谢、生产和毒理学数据的组合将用于支持IND和未来的临床试验。

DESCRIPTION (provided by applicant): With recent unsettling events foreshadowing an increased sense of urgency, NIAID has targeted research and development of therapeutics, vaccines, adjuvants/immunostimulants, and diagnostics for smallpox (variola). TSRL was granted a Phase I SBIR to explore prodrug strategies to increase the oral availability of potential anti-smallpox drugs. Strategies that can improve the oral bioavailability of approved drugs as well as potential drug candidates will facilitate the development of more effective antiviral agents and reduce undesirable outcomes such as drug toxicity, poor patient compliance, and high costs. The long-term goal of this project for biodefense is to improve the oral absorption of potent, but poorly absorbed anti-pox agents by designing prodrugs targeted to transporters expressed in human intestine and able to be activated by endogenous esterases or amidases that release the absorbed drug in vivo from its prodrug form. For this project, we established collaborations with Prof. Charles McKenna (prodrug design and synthesis) at the University of Southern California and Prof. John Drach (virological studies) at the University of Michigan. The work in the Phase I project focused chiefly on prodrugs of cyclic cidofovir (cHPMPC), a broad spectrum antiviral compound with potent activity against variola and other orthopox viruses, but of limited value in a smallpox epidemic due to its very low oral bioavailability. We demonstrated that dipeptide prodrugs of cHPMPC, which were first discovered in Prof. McKenna's laboratory, have great potential for oral delivery. Our results from an animal oral bioavailability model indicate that absorption of the first generation of dipeptide prodrugs is up to an order of magnitude greater than that of the parent drug cHPMPC, and that a significant fraction of the absorbed prodrug is converted to drug in vivo. In this Phase II SBIR proposal, we have devised a synthetic strategy and SAR plan to optimize the bioavailability of this new class of prodrug. We have formed a collaborative network of researchers and specialists that will allow us to systematically test a diverse library of novel cHPMPC dipeptide conjugates for stability, transport, drug oral bioavailability, and efficacy in accepted animal models. The compound or compounds showing the best oral absorption and efficacy will be manufactured following GMP requirements and tested for toxicity. The combined portfolio of pharmacokinetic, metabolism, manufacturing and toxicological data will be used in support of an IND and future clinical testing. The long term objective of this project is to make new oral drugs for the treatment of small pox. The expertise needed to succeed in this project will be provided by personnel at TSRL, Inc. in collaboration with Dr. John Drach, an expert in the area of antiviral drugs at the University of Michigan, and Dr. Charles Mckenna at the University of Southern California, who is well experienced at organic and medicinal chemistry of phosphorous containing compounds.